Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT07213817 #2025-522139-33-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
3 recruiting sites
Ipsen
Phase 1 / Phase 2 Breast cancer Stomach and esophageal cancer Sarcoma and GIST Cervical / Vulvar / Vaginal cancer #NCT06795412 #2025-521828-30-00
Required histologic types
Stomach Oesogastric junction Bone sarcoma Soft tissue sarcoma Cervical cancer
Required histologic sub types
Adenocarcinoma Osteosarcoma Chordoma Squamous cell carcinoma Adenosquamous carcinoma
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative HR Positive
Required disease stage
Locally Advanced Metastatic
4 recruiting sites
Pyxis Oncology, Inc
Phase 1 / Phase 2 Head and neck cancer #NCT06795412 #2025-521828-30-00
Required histologic types
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None 1 2 3 or more
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
Pyxis Oncology, Inc
Phase 1 / Phase 2 Breast cancer #NCT05386108 #2024-512878-98-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
Stemline Therapeutics, Inc.
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Cervical / Vulvar / Vaginal cancer #NCT07169734 #2025-521441-24-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Cervical cancer
Required histologic sub types
Squamous NSCLC Adenocarcinoma Intrahepatic cholangiocarcinoma Urothelial carcinoma Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
4 recruiting sites
Alentis Therapeutics AG
Phase 1 / Phase 2 Lung cancer Colon cancer Rectal cancer Stomach and esophageal cancer Head and neck cancer #NCT07151040 #2024-519639-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer) Stomach Oesogastric junction Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
One-carbon Therapeutics AB
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT07222488 #2025-520467-40-00
Required histologic types
Non-invasive bladder cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None 1
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery Immunotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive
1 recruiting site
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Breast cancer #NCT05768139 #2023-000442-41
Required HER2 statuses
HER2 Negative HER2 Low
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2 Prostate cancer #NCT07226986 #2025-521859-23-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required PSMA PET Scan statuses
PSMA PET Positive
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
4 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors #NCT05118789
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ROS-1
Required number of previous lines of therapy for current stage of disease
1
4 recruiting sites
Nuvalent Inc.